Allschwil, Switzerland

Bérangère Gaucher

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Redona Therapeutics, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bérangère Gaucher. Retrieved from https://idiyas.com/inventor/bérangère-gaucher-o23hp183

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bérangère Gaucher - Innovator in Cancer Treatment

Introduction: Bérangère Gaucher is an inventor based in Allschwil, Switzerland. He is currently associated with Redona Therapeutics, Inc., where he focuses on developing innovative solutions for cancer treatment. Despite having no granted patents to his name, his contributions to the field of medicinal chemistry are noteworthy.

Latest Patent Applications: Bérangère Gaucher's recent patent application is titled "Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer." This invention provides compounds of formula (IA) and compounds of formula (IB), along with pharmaceutically acceptable salts. The compounds are designed to treat neoplastic diseases, particularly cancer, utilizing specific chemical structures and methods outlined in the claims.

Conclusion: Bérangère Gaucher is making significant strides in the field of cancer treatment through his innovative research and patent applications. His work at Redona Therapeutics, Inc. highlights the importance of developing new therapeutic compounds to combat cancer effectively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…